Dianthus Therapeutics Inc. Company Profile
NASDAQ: DNTHHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
Dianthus Therapeutics at a glance
Dianthus Therapeutics Inc. (NASDAQ: DNTH) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in New York, NY. Dianthus Therapeutics is led by Mr. Marino Garcia M.B.A. and employs about 92 people. The company's shares have traded publicly since 2018.
At a market capitalization of $4.78 billion, it is considered a mid-cap company. Its SEC Central Index Key (CIK) is 0001690585, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Dianthus Therapeutics do?
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Business description based on the company's public filings.
Company information
- Legal name
- Dianthus Therapeutics Inc.
- Ticker
- NASDAQ: DNTH
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Marino Garcia M.B.A.
- Employees
- 92
- Headquarters
- 7 Times Square, New York, NY, United States
- Phone
- 929 999 4055
- Website
- dianthustx.com
- IPO year
- 2018
- Market cap
- $4.78B
- SEC CIK
- 0001690585
Companies similar to Dianthus Therapeutics
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| MANEVeradermics Incorporated | 110.95 | +1.83% | $4.64B | vs DNTH |
| ERASErasca Inc. | 14.12 | -1.26% | $4.94B | vs DNTH |
| TVTXTravere Therapeutics Inc. | 53.44 | -4.54% | $5.04B | vs DNTH |
| GRFSGrifols S.A. ADR | 7.50 | -0.27% | $5.10B | vs DNTH |
| COGTCogent Biosciences Inc. | 30.14 | -0.79% | $5.23B | vs DNTH |
| MIRMMirum Pharmaceuticals Inc. | 80.64 | +1.75% | $5.24B | vs DNTH |
| EWTXEdgewise Therapeutics Inc. | 39.57 | -1.12% | $4.30B | vs DNTH |
| PTCTPTC Therapeutics Inc. | 63.23 | -0.74% | $5.28B | vs DNTH |